Jevtana 60 mg, 1 vial (Cabazitaxel 60 mg / 1.5 ml concentrate) by Sanofi.
Indications: Metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen, with prednisone/prednisolone.
Administration: Intravenous infusion of 25 mg/m² every 3 weeks.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Sanofi |
| Active ingredient | Cabazitaxel 60 mg / 1.5 ml concentrate (with diluent) — taxane. |
| Strength & pack | 1 vial concentrate + 1 vial solvent. |
| Form | Concentrate and solvent for solution for infusion |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |